缺氧与免疫表型相关融合模型用于TACE治疗肝细胞癌的无创预后预测:多中心研究
本研究纳入1448例肝细胞癌患者,利用治疗前增强CT构建深度学习与常规影像组学模型,比较早期与晚期融合模型,并整合临床变量形成临床-影像模型(CRM)。CRM在多个独立队列中有效分层生存,且比现有临床模型更精细;多组学分析显示高评分组存在缺氧通路激活和细胞毒性T细胞活性降低。
要点
- CRM可无创预测TACE治疗HCC患者的生存预后。
- CRM在多个独立队列中实现比现有临床模型更精细的风险分层。
- 高评分组显示缺氧通路激活、糖酵解上调及细胞毒性T细胞活性降低。
核心结论
- CRM模型可无创预测接受TACE治疗的HCC患者预后,并实现比现有临床模型更精细的风险分层。
研究设计与样本
- 多中心研究纳入1448例HCC患者,包括TACE队列(n=1349)、随机试验生物标志物亚组(n=41)、单细胞RNA测序队列及TCGA HCC队列(n=50)。
- 利用治疗前增强CT构建深度学习与常规影像组学模型,比较早期融合与晚期融合模型(LFM),并将更优LFM与临床变量整合形成临床-影像模型(CRM)。
主要发现
- CRM在多个独立队列中有效分层患者生存,并实现比现有临床模型更精细的风险分层。
- 多组学分析显示LFM高评分组中myelocytomatosis oncogene激活、上皮-间质转化增强、糖酵解上调及缺氧通路激活。
- 单细胞转录组数据证实高风险患者中几乎所有细胞类型缺氧评分高,且细胞毒性T细胞细胞毒性活性降低。
关键数值与推荐
- 纳入TACE队列1349例、随机试验生物标志物亚组41例、TCGA HCC队列50例。
临床怎么用
- CRM模型可基于治疗前增强CT和临床变量无创预测TACE治疗的HCC患者预后,辅助风险分层。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Survival outcomes after transarterial chemoembolisation (TACE) vary in hepatocellular carcinoma (HCC) patients, and existing prognostic scores and imaging models often lack generalisability and biological interpretability. OBJECTIVE: To develop and validate a multimodal prognostication model for HCC that allows for a precise assessment of survival outcomes of HCC patients receiving TACE therapy. DESIGN: This study enrolled 1448 HCC patients, including a TACE cohort (n=1349), a biomarker subset from a randomised trial (n=41), a single-cell RNA sequencing cohort and The Cancer Genome Atlas (TCGA) HCC cohort (n=50). Pre-treatment contrast-enhanced CT images were used to construct deep learning and conventional radiomic models. The early-fusion and late-fusion models (LFMs) were compared, and a clinical-radiologic model (CRM) was formed by integrating the better-performing LFM with clinical variables. Using TCGA data and single-cell transcriptomic profiles, the differences between high-score and low-score groups in tumour immune microenvironment, cellular functional states and key signalling pathways were investigated. RESULTS: The CRM effectively stratified patients' survival across multiple independent cohorts and achieved more granular risk stratification than the existing clinical models. Multi-omic analyses revealed that in the LFM high-score group, myelocytomatosis oncogene was activated, epithelial-mesenchymal transition enhanced, glycolysis upregulated and hypoxia pathway activated. Single-cell transcriptomic data confirmed that virtually all cell types in high-risk patients scored high in hypoxia, and cytotoxic T cells had a reduced cytotoxic activity. CONCLUSION: The CRM model can non-invasively predict the prognosis of HCC patients treated by TACE therapy.
引用
- Guo Y, Zhang G, Fu X, et al. Hypoxia-related and immune phenotype-related fusion model for non-invasive prognostication of hepatocellular carcinoma treated by TACE: a multicentre study. Gut. 2026. PMID: 41856522. doi:10.1136/gutjnl-2025-337938
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。